GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+3.04%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$423M
AUM Growth
+$423M
(-5.4%)
Cap. Flow
-$17.9M
Cap. Flow
% of AUM
-4.24%
Top 10 Holdings %
Top 10 Hldgs %
53.11%
Holding
44
New
13
Increased
9
Reduced
9
Closed
6
Top Buys
| 1 |
BioAtla
BCAB
|
$24.8M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$16.1M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$15.4M |
| 4 |
Cytokinetics
CYTK
|
$14M |
| 5 |
UroGen Pharma
URGN
|
$12.6M |
Top Sells
| 1 |
Insulet
PODD
|
$28.7M |
| 2 |
United Therapeutics
UTHR
|
$16.6M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$16.2M |
| 4 |
Collegium Pharmaceutical
COLL
|
$14.6M |
| 5 |
Ocular Therapeutix
OCUL
|
$13M |
Sector Composition
| 1 | Healthcare | 94.11% |
| 2 | Real Estate | 2.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rigel Pharmaceuticals
RIGL
$710M
| $7.19M | 1.67% |
1,980,000
+480,000
| +32% | +$1.74M |
|
27
Spyre Therapeutics
SYRE
$1.02B
| $7.16M | 1.67% |
900,000
| – | – |
|
28
Phathom Pharmaceuticals
PHAT
$843M
| $7.09M | 1.65% |
+220,863
| New | +$7.09M |
|
29
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $5.47M | 1.27% |
+480,000
| New | +$5.47M |
|
30
Vaxcyte
PCVX
$4.17B
| $2.49M | 0.58% |
+98,061
| New | +$2.49M |
|
31
Repare Therapeutics
RPTX
$73.9M
| $2.44M | 0.57% |
93,137
-342,952
| -79% | -$9M |
|
|
32
Collegium Pharmaceutical
COLL
$1.25B
| $2.4M | 0.56% |
121,342
-740,068
| -86% | -$14.6M |
|
33
Amicus Therapeutics
FOLD
$2.42B
| $2.38M | 0.55% |
249,000
-1,351,000
| -84% | -$12.9M |
|
34
InflaRx
IFRX
$117M
| $1.43M | 0.33% |
551,918
-1,648,082
| -75% | -$4.27M |
|
35
ProQR Therapeutics
PRQR
$256M
| $254K | 0.06% |
+30,336
| New | +$254K |
|
|
XENT
36
DELISTED
Intersect ENT, Inc
XENT
| – | – |
-700,000
| Closed | -$12M |
|
|
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-100,000
| Closed | -$16.2M |
|
|
VERV
38
DELISTED
Verve Therapeutics
VERV
| – | – |
-35,000
| Closed | -$2.11M |
|
|
39
Insulet
PODD
$24.2B
| – | – |
-104,600
| Closed | -$28.7M |
|
|
40
Ocular Therapeutix
OCUL
$2.25B
| – | – |
-919,887
| Closed | -$13M |
|
41
Intellia Therapeutics
NTLA
$1.26B
| – | – |
0
| – | – |
|
42
Kura Oncology
KURA
$732M
| – | – |
-500,000
| Closed | -$10.4M |
|
43
FibroGen
FGEN
$48.4M
| – | – |
0
| – | – |
|
44
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
0
| – | – |
|